Mahesh V. Patel, Ph.D (President and CEO) has more than 20 years of technology and product development experience in the area of drug discovery support, drug delivery and product line extensions. Prior to co-founding Lipocine in 1997, Patel led drug delivery research and development at Pharmacia and Upjohn, Kalamazoo, MI. He received his MS in Physical Pharmacy at the University of Cincinnati and his PhD in Pharmaceutics from the University of Utah. His areas of expertise include strategic planning, technology assessment/development, technical management and product research and development.

Srinivasan Venkateshwaran, Ph.D (CTO and VP of Research and Development) has more than 20 years of experience in leading the development of innovative drug delivery-based technologies and products at several drug delivery companies. He has held positions as Executive Director of R&D at Mylan Technologies Inc. and Executive Director of Transdermal and Inhalation Research at TheraTech Inc. /Watson Labs, Salt Lake City, UT, where he spearheaded technology and product development. Venkateshwaran received his PhD/MS in Chemical Engineering from the University of Utah and a B Tech in Chemical Engineering from the Indian Institute of Technology, Mumbai, India.

Gerald T. Simmons (Corporate Business Development Officer) brings 25+ years of large pharmaceutical and early stage drug development company experience. Simmons has held corporate business positions at Pharmacraft (now Ciba-Geigy) and VP of New Venture Group at Schering Plough Corp. After Schering Plough, he held CEO assignments for Cellegy Pharmaceuticals, a drug delivery company, MantiCore Pharmaceuticals, an oncology company and Fountain Pharmaceuticals, a drug delivery company. He managed Cellegy from a seed financing stage through an IPO (NASDAQ-CLGY). Simmons received his MBA from the University of Buffalo and BA from Canisius College.

Robert K. Merrell (VP of Finance) has more than 20 years of financial and general management experience in the pharmaceutical industry. He was a VP at Myriad Genetics Laboratories and CFO at NPS Pharmaceuticals. At NPS he provided financial leadership in enabling NPS' growth from an early stage company through successful IPO and three subsequent follow-on offerings raising approximately $300 million. He was also actively involved in mergers and acquisitions. Prior to NPS, he was a senior manager at KPMG Peat Marwick. He is a CPA and earned his Master of Management Degree at Kellogg Graduate School of Management and his Bachelor Degree in Accounting at the University of Utah.